An Open-Label, Multi-Center Expanded Access Program of Abemaciclib for the Treatment of Hormone Receptor Positive, HER2 Negative Advanced or Metastatic Breast Cancer in Patients With Disease Progression on Prior Therapies
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Abemaciclib (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Eli Lilly and Company
- 27 Oct 2017 Status changed from recruiting to completed.
- 13 Jun 2016 New trial record